Incyte Stock Financials

INCY -  USA Stock  

USD 65.56  0.22  0.33%

Understanding current and past Incyte Corp Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Incyte Corp's financial statements are interrelated, with each one affecting the others. For example, an increase in Incyte Corp's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Incyte Corp's financials over time to get the whole picture.
Incyte Corp Average Assets are fairly stable at the moment as compared to the past year. Incyte Corp reported Average Assets of 3.21 Billion in 2020. Average Equity is likely to rise to about 2.5 B in 2021, whereas Net Income Per Employee is likely to drop (170.7 K) in 2021.
Use fundamental data analysis to validate all available fundamentals of Incyte Corp to find out if markets are presently mispricing the company. We were able to break down thirty-five available reported financial drivers for Incyte Corp, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Incyte Corp financials, including its shares owned by institutions, debt to equity, working capital, as well as the relationship between the gross profit and price to earnings to growth . Given that Incyte Corp has a number of shares shorted of 5.86 M, we strongly advise you to confirm Incyte Corp regular market performance to make sure the company can sustain itself down the road. Use Incyte Corp to protect your portfolios against small market fluctuations. The stock experiences a normal downward trend and little activity. Check odds of Incyte Corp to be traded at $64.9 in 90 days.

Incyte Fundamentals 

 
Refresh
With this module, you can analyze Incyte financials for your investing period. You should be able to track the changes in Incyte Corp individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Incyte Corp is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Incyte Corp includes many different criteria found on its balance sheet. For example, investors should never minimize Incyte Corp's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Incyte Corp's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Incyte Corp.

Incyte Corp Cash

  Chance Of Financial Distress
Less than 50
Incyte Corp has    50 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Incyte Corp stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Incyte Corp's official financial statements usually reflect Incyte Corp's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Incyte Corp. For example, before you start analyzing numbers published by Incyte accountants, it's critical to develop an understanding of what Incyte Corp's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Incyte Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte Corp's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Incyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte Corp. Please utilize our Beneish M Score to check the likelihood of Incyte Corp's management to manipulate its earnings.

Incyte Corp Company Summary

Incyte Corp competes with Arbutus Biopharma, Arca Biopharma, Abvc Biopharma, Acadia Pharmaceutica, and Adicet Bio. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases itacitinib, which is in Phase III clinical trial to treat nave chronic GVHD and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd. Eli Lilly and Company Agenus Inc. Calithera Biosciences, Inc MacroGenics, Inc. Merus N.V. Syros Pharmaceuticals, Inc. Innovent Biologics, Inc. Zai Lab Limited and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0000879169
ISINUS45337C1027
CUSIP45337C102
RegionNorth America
LocationDelaware; U.S.A
Business Address1801 Augustine Cut
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.incyte.com
Phone302 498 6700
CurrencyUSD - US Dollar

Incyte Corp Key Financial Ratios

Generally speaking, Incyte Corp's financial ratios allow both analysts and investors to convert raw data from Incyte Corp's financial statements into concise, actionable information that can be used to evaluate the performance of Incyte Corp over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Incyte Corp reports annually and quarterly.

Incyte Corp Key Balance Sheet Accounts

201620172018201920202021 (projected)
Inventories4.11 M6.48 M6.97 M11.4 M16.43 M17.72 M
Receivables148.76 M266.3 M307.6 M308.81 M481.99 M520.05 M
Accounts Payable75.6 M67.67 M103.83 M83.65 M98.77 M106.56 M
Total Assets1.64 B2.3 B2.65 B3.43 B3.56 B3.84 B
Current Assets994.18 M1.5 B1.83 B2.48 B2.36 B1.89 B
Assets Non Current644.42 M797.73 M813.51 M945.26 M1.2 B1.3 B
Cash and Equivalents653.23 M900.43 M1.16 B1.83 B1.51 B1.25 B
Total Debt651.48 M24 M17.43 M50.88 M34.86 M35.77 M
Debt Non Current651.48 M16.61 M17.43 M31.92 M32.57 M33.43 M
Shareholders Equity419.47 M1.63 B1.93 B2.6 B2.61 B2.82 B
Inventory19.3 M14.45 M10.4 M16.5 M35.97 M38.81 M
Investments188.19 M404.49 M373.54 M418.53 M510.67 M550.99 M
Investments Current156.2 M270.14 M274.34 M284.87 M288.37 M239.21 M
Total Liabilities1.22 B671.95 M719.79 M828.34 M949.65 M950.64 M
Current Liabilities273.5 M375.4 M425.28 M513.34 M631.2 M681.03 M

Incyte Corp Key Income Statement Accounts

201620172018201920202021 (projected)
Direct Expenses58.19 M79.48 M94.12 M114.25 M131.33 M141.7 M
Consolidated Income104.22 M(313.14 M)109.49 M446.91 M(295.7 M)(303.48 M)
Cost of Revenue58.19 M79.48 M94.12 M114.25 M131.33 M141.7 M
Gross Profit1.05 B1.46 B1.79 B2.04 B2.54 B2.74 B
Interest Expense38.74 M6.9 M1.54 M1.85 M2.17 M2.23 M
Net Income104.22 M(313.14 M)109.49 M446.91 M(295.7 M)(303.48 M)
Operating Expenses885.11 M1.69 B1.63 B1.62 B2.78 B2.99 B
Operating Income162.42 M(235.68 M)155.4 M421.69 M(240.29 M)(246.61 M)
Revenues1.11 B1.54 B1.88 B2.16 B2.67 B2.88 B
Income Tax Expense3.18 M852 K5.85 M39.88 M63.48 M68.49 M

Incyte Corp Key Cash Accounts

201620172018201920202021 (projected)
Capital Expenditure(120.28 M)(111.02 M)(73.48 M)(78.06 M)(187.38 M)(192.31 M)
Depreciation Amortization and Accretion58.42 M52.18 M54.97 M54.53 M51.81 M51.94 M
Net Cash Flow or Change in Cash and Cash Equivalents116.88 M247.21 M264.55 M668.72 M(318.94 M)(327.34 M)
Issuance Purchase of Equity Shares49.97 M716.15 M29.94 M63.3 M110.31 M126.63 M
Net Cash Flow from Financing44.62 M690.21 M14.66 M45.71 M71.71 M103.13 M
Net Cash Flow from Investing(232.49 M)(349.98 M)(86.42 M)(87.45 M)(269 M)(276.08 M)
Net Cash Flow Investment Acquisitions and Disposals30.64 M(238.96 M)(12.94 M)(9.39 M)(81.62 M)(83.77 M)
Net Cash Flow from Operations304.76 M(92.99 M)336.23 M710.66 M(124.6 M)(127.88 M)
Share Based Compensation96.2 M133.06 M148.15 M166.59 M177.88 M144.91 M

Incyte Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Incyte Corp's current stock value. Our valuation model uses many indicators to compare Incyte Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Incyte Corp competition to find correlations between indicators driving Incyte Corp's intrinsic value. More Info.
Incyte Corp is rated second overall in total debt category among related companies. It is currently regarded as number one stock in current liabilities category among related companies creating about  4.91  of Current Liabilities per Total Debt. . Incyte Corp Total Debt is fairly stable at the moment as compared to the past year. Incyte Corp reported Total Debt of 34.86 Million in 2020

Incyte Corp Systematic Risk

Incyte Corp's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Incyte Corp volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Incyte Corp correlated with the market. If Beta is less than 0 Incyte Corp generally moves in the opposite direction as compared to the market. If Incyte Corp Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Incyte Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Incyte Corp is generally in the same direction as the market. If Beta > 1 Incyte Corp moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Incyte Corp Financials

What exactly are Incyte Corp Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Incyte Corp's income statement, its balance sheet, and the statement of cash flows. Potential Incyte Corp investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Incyte Corp investors may use each financial statement separately, they are all related. The changes in Incyte Corp's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Incyte Corp's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2018 2019 2020 2021 (projected)
Receivables307.6 M308.81 M481.99 M520.05 M
Inventories6.97 M11.4 M16.43 M17.72 M
This Stock does not participate in any thematic ideas. You can create a thematic portfolio hereView All Thematic Ideas

Incyte Corp October 17, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Incyte Corp help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Incyte Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Incyte Corp based on widely used predictive technical indicators. In general, we focus on analyzing Incyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Incyte Corp's daily price indicators and compare them against related drivers.
Information Ratio(0.19)
Maximum Drawdown10.76
Value At Risk(2.24)
Potential Upside2.18
Please see Risk vs Return Analysis. Note that the Incyte Corp information on this page should be used as a complementary analysis to other Incyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Incyte Stock analysis

When running Incyte Corp price analysis, check to measure Incyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte Corp is operating at the current time. Most of Incyte Corp's value examination focuses on studying past and present price action to predict the probability of Incyte Corp's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Incyte Corp's price. Additionally, you may evaluate how the addition of Incyte Corp to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
The market value of Incyte Corp is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte Corp's value that differs from its market value or its book value, called intrinsic value, which is Incyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte Corp's market value can be influenced by many factors that don't directly affect Incyte Corp underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine Incyte Corp value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.